Evidence-based public policy making formedicines across countries: findings andimplications for the future
No Thumbnail Available
Date
2021
Journal Title
Journal ISSN
Volume Title
Publisher
Future Medicine Ltd
Abstract
im:Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence ofnon-communicable diseases (NCDs) and new premium priced medicines for cancer, orphan diseases andother complex areas. This is difficult to sustain without reforms.Methods:Extensive narrative review ofpublished papers and contextualizing the findings to provide future guidance.Results:New models arebeing introduced to improve the managed entry of new medicines including managed entry agreements,fair pricing approaches and monitoring prescribing against agreed guidance. Multiple measures have alsosuccessfully been introduced to improve the prescribing of established medicines. This includes encour-aging greater prescribing of generics and biosimilars versus originators and patented medicines in a classto conserve resources without compromising care. In addition, reducing inappropriate antibiotic utiliza-tion. Typically, multiple measures are the most effective.Conclusion:Multiple measures will be needed toattain and retain universal healthcare.
Keywords:antimicrobials•biosimilars•COVID-19•demand-side measures•generics•guidelines•managedentry•oncology•orphan medicines•quality indicators•statins
Description
Journal article
Keywords
Research Subject Categories::MEDICINE::Physiology and pharmacology::Pharmacological research::Clinical pharmacology
Citation
Godman, B., Fadare, J., Kwon, H. Y., Dias, C. Z., Kurdi, A., Dias Godoi, I. P., ... & Meyer, J. C. (2021). Evidence-based public policy making for medicines across countries: findings and implications for the future. Journal of comparative effectiveness research, 10(12), 1019-1052.